Crystallography Identifies Protease Inhibitor

  • ChemPubSoc Europe Logo
  • Author: Angewandte Chemie International Edition
  • Published Date: 26 March 2019
  • Source / Publisher: Angewandte Chemie International Edition/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Crystallography Identifies Protease Inhibitor

Peptides play an important role in modulating biological processes, such as signaling and cell death. They could, thus, be useful in the pharmaceutical industry. There are a few dozen peptide therapeutics already on the market and over 150 in active clinical development. However, it is challenging to discover new peptide inhibitors for therapeutically relevant proteins.


Rainer Riedl, Zurich University of Applied Sciences, Wädenswil, Switzerland, and colleagues have discovered a peptide ligand which can inhibit the activity of a therapeutic target, matrix metalloproteinase 13 (MMP-13). MMPs are a family of zinc-containing enzymes that contribute to the degradation of extracellular matrix proteins. They are involved in diseases such as cancer.


The team performed co-crystallization experiments with MMP-13 and small molecule inhibitors of the enzyme. Surprisingly, the team identified a pentapeptide ligand instead of the investigated inhibitors in the catalytic groove of MMP-13 (crystal structure pictured). This bound pentapeptide is a fragment of MMP‐13, created by self‐degradation of the enzyme.


Based on this discovery, the team developed optimized inhibitors with similar structures (peptidomimetics). They obtained a potent inhibitor which is membrane-permeable and shows a promising selectivity profile toward anticancer drug targets. The study demonstrates that crystallization studies can be useful for the discovery of protease ligands suitable for drug optimization.


 

Article Views: 817

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH